ProPhase Labs, Inc. (NASDAQ:PRPH) Director Jason Michael Barr sold 4,379 shares of the firm’s stock in a transaction that occurred on Friday, September 29th. The shares were sold at an average price of $2.30, for a total transaction of $10,071.70. Following the completion of the sale, the director now owns 7,721 shares in the company, valued at $17,758.30. The transaction was disclosed in a document filed with the SEC, which is available at this link.

ProPhase Labs, Inc. (NASDAQ:PRPH) traded up 2.44% during midday trading on Thursday, reaching $2.10. 1,969 shares of the company traded hands. The stock’s 50 day moving average is $2.22 and its 200 day moving average is $2.08. The company has a market capitalization of $33.95 million, a price-to-earnings ratio of 0.87 and a beta of 0.02. ProPhase Labs, Inc. has a one year low of $1.78 and a one year high of $2.45.

ProPhase Labs (NASDAQ:PRPH) last issued its quarterly earnings results on Friday, August 11th. The company reported ($0.09) EPS for the quarter. ProPhase Labs had a net margin of 270.98% and a return on equity of 54.87%. The business had revenue of $1.91 million for the quarter.

ProPhase Labs declared that its Board of Directors has approved a share repurchase plan on Tuesday, August 15th that allows the company to buyback 4,000,000 outstanding shares. This buyback authorization allows the company to purchase shares of its stock through a tender offer. Stock buyback plans are typically a sign that the company’s board of directors believes its shares are undervalued.

TRADEMARK VIOLATION NOTICE: “ProPhase Labs, Inc. (PRPH) Director Sells $10,071.70 in Stock” was reported by Watch List News and is owned by of Watch List News. If you are reading this piece of content on another website, it was illegally copied and republished in violation of United States and international trademark & copyright laws. The original version of this piece of content can be accessed at https://www.watchlistnews.com/prophase-labs-inc-prph-director-sells-10071-70-in-stock/1610103.html.

Separately, ValuEngine downgraded shares of ProPhase Labs from a “hold” rating to a “sell” rating in a research report on Thursday.

ProPhase Labs Company Profile

ProPhase Labs, Inc manufactures, markets and distributes a range of homeopathic and healthcare products. The Company is engaged in the research and development of over-the-counter (OTC) drugs and natural base health products, including supplements, personal care and cosmeceutical products. The Company’s products include TK Supplements and ORXx Complete.

Receive News & Ratings for ProPhase Labs Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProPhase Labs Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.